Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Aug 21;19(31):5051-60.
doi: 10.3748/wjg.v19.i31.5051.

Role of bevacizumab in colorectal cancer growth and its adverse effects: a review

Efstathios T Pavlidis  1 , Theodoros E Pavlidis
Affiliations
Review

Role of bevacizumab in colorectal cancer growth and its adverse effects: a review

Efstathios T Pavlidis et al. World J Gastroenterol. .

Abstract

Angiogenesis affects both wound healing and malignant cell growth through nutrients and oxygen. Vascular endothelial growth factor (VEGF) is the most important element involved in this complex process. Inhibition of VEGF influences angiogenesis and may restrict tumor growth and metastatic ability. Modern anti-angiogenic therapy is based on this theory. Bevacizumab is a recombinant humanized monoclonal antibody (immunoglobulin G1) which binds with VEGF-A forming a large molecule. It can not be bound with VEGF tyrosine kinase receptors preventing VEGF-A incorporation; thus its activity is inhibited inducing blockage of VEGF-mediated angiogenesis. Bevacizumab, in combination with chemotherapy or other novel targeted therapeutic agents, is currently used more frequently in clinical practice, mainly for managing advanced colorectal cancer. It is also used for managing other malignancies, such as breast cancer, pancreatic cancer, prostate cancer, non small-cell lung cancer, metastatic renal carcinoma and ovarian tumors. Although it is generally considered a safe treatment, there are reports of some rare side effects which should be taken into account. Recent experiments in rats and mice show promising results with a wider therapeutic range.

Keywords: Angiogenesis; Anti-angiogenic agents; Avastin; Bevacizumab; Cancer targeted therapy; Colorectal cancer; Vascular endothelial growth factor.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The process of angiogenesis and the mechanism of action of bevacizumab. A: The malignant cells secrete vascular endothelial growth factor (VEGF)-A; B: It is incorporated with its tyrosine kinase receptors (VEGFRs), promoting endothelial cell proliferation and migration; C: It leads to increased angiogenesis inducing tumor growth; D: Bevacizumab is combined with VEGF-A forming a new large molecule that lacks the ability to bind with its receptors; thus avoiding its incorporation and action, it then inhibits angiogenesis. Taken from Shord et al[15].
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Kajdaniuk D, Marek B, Foltyn W, Kos-Kudła B. Vascular endothelial growth factor (VEGF) - part 1: in physiology and pathophysiology. Endokrynol Pol. 2011;62:444–455. - PubMed
    1. Kajdaniuk D, Marek B, Foltyn W, Kos-Kudła B. Vascular endothelial growth factor (VEGF) - part 2: in endocrinology and oncology. Endokrynol Pol. 2011;62:456–464. - PubMed
    1. Takahashi S. Vascular endothelial growth factor (VEGF), VEGF receptors and their inhibitors for antiangiogenic tumor therapy. Biol Pharm Bull. 2011;34:1785–1788. - PubMed
    1. Ichihara E, Kiura K, Tanimoto M. Targeting angiogenesis in cancer therapy. Acta Med Okayama. 2011;65:353–362. - PubMed
    1. Bruce D, Tan PH. Vascular endothelial growth factor receptors and the therapeutic targeting of angiogenesis in cancer: where do we go from here? Cell Commun Adhes. 2011;18:85–103. - PubMed

MeSH terms

Substances